Skip Main Navigation | Skip to Content

Innovators honored once again

Spotlight Item Photo
Click to open photo
Bookmark and Share

January 2013

Thirteen researchers from the College of Medicine – two more than last year – were among those honored at Florida State’s Eighth Annual Innovators Reception in late 2012. The annual event is sponsored by the Office of Intellectual Property Development and Commercialization.

Twelve of the College of Medicine honorees have a past or present link to the Department of Biomedical Sciences. In alphabetical order, they are Virginia Baker, Ph.D., former postdoctoral fellow in the lab of Department Chair Richard Nowakowski; Professor Pradeep Bhide, Ph.D.; Research Assistant Professor Ewa Bienkiewicz, Ph.D.; Professor Michael Blaber, Ph.D.; Professor Myra Hurt, Ph.D., senior associate dean for research and graduate programs; Assistant Professor Sanjay Kumar, Ph.D.; Associate Professor Choogon Lee, Ph.D.; Associate Professor James Olcese, Ph.D.; Professor Mike Overton, Ph.D.; Raed Rizkallah, Ph.D., postdoc in the Hurt lab; Associate Professor Branko Stefanovic, Ph.D.; and Assistant in Medicine Jacob VanLandingham, Ph.D. Also recognized was Michele Manting, M.D., M.Ed., formerly in the Department of Clinical Sciences.

Researchers from across the campus were recognized for their work in the fiscal year ending June 30. Some had had their technology commercialized through a license or option agreement. Some had received funding from the Florida State Research Foundation GAP program when it seemed their research results could lead to public availability of a new product or service. Some were recognized for patents issued, patent applications filed or disclosures submitted. Below are the specifics on the College of Medicine honorees.


  • Was recognized for submitting disclosure statements regarding “Methods of Identifying Novel Biomarkers.”


  • Submitted disclosure statements regarding “Novel Class of Non-Stimulant Treatment for ADHD and Related Disorders.”


  • Received GAP funding for her project “Vascular Injury Treatment,” with the mission statement to develop and test a novel therapeutic agent that will alleviate cell death and accelerate healing of vascular injuries.
  • Filed U.S. Patent Application No. 13/446,205, 4/13/2012, “Prion Protein Based Hemin Binders and Methods of Use.”


  • Was recognized for developing a family of mutant human and mouse antibodies that could be useful to accelerate wound healing. FSU has licensed some of these antibodies to KeraFAST to market, sell and distribute on its e-commerce website to academic and industrial research laboratories worldwide.
  • Received (along with Joe Schlenoff from the Chemistry Department) GAP funding for their joint project “Novel Biocompatible Polymer Material Using Engineered Human Fibroblastic Growth Factor-1 for Accelerated Wound Healing.” The mission is to develop a novel wound healing approach by combining Schlenoff's biocompatible polymer material called saloplastic with Blaber’s engineered form of fibroblast growth factor (FGF-1).
  • Had these patents issued: No. 8,153,770 (issued 4/10/2012), No. 8,119,776 (2/12/2012), No. 8,153,771 (4/10/2012), “Mutants of Human Fibroblast Growth Factor Having Increased Stability and/or Mitogenic Potency.”
  • Submitted disclosure statements regarding “An Empirical Phase Diagram Approach to Investigate Conformational Stability of ‘Second Generation’ Functional Mutants of Acidic Fibroblast Growth Factor (FGF-1) Novel Biocompatible Polymer Material Using Human Growth Factors for Accelerated Wound Healing.”

Hurt and Rizkallah:

  • Have developed a novel biomarker that identifies a specific cell stage. FSU licensed these polyclonal antibodies to Millipore Inc. to develop research reagents and kits.
  • Filed U.S. Patent Application No. 13/235,882, 9/19/2011, “Antibody Biomarker Specific for Mitotic Cells and Related Methods.”


  • Has developed a novel brain-tissue preservation chamber that has been made commercially available by KeraFAST, a company that specializes in marketing small amounts of unique reagents.
  • Filed U.S. Patent Application No. 13/353,914, 1/19/2012, “Specimen Preservation Chamber and Method.”
  • Submitted disclosure statements regarding “PuLSyR – Photouncaging-Assisted Evaluation of Large-Scale Synaptic Reorganization of Brain Circuits.”


  • Has developed polyclonal antibodies that are important for regulating the circadian clock mechanism. FSU has licensed these unique antibodies through KeraFAST to other researchers.
  • Submitted disclosure statements regarding “Polyclonal Antibodies Against PERIOD2 Protein in Guinea Pig.”


  • Submitted disclosure statements regarding “Self-Examination Breast Cancer Mobile App.”


  • Submitted disclosure statements regarding “Photic Suppression of Uterine Contractions During Pregnancy” and “Melatonin and the Circadian Timing of Human Parturition.”


  • Received (with Amy Sang in Chemistry) GAP funding for their joint project “Putative Therapeutic Agents to Treat Obesity in Animal Models,” with the mission statement to test the efficacy and safety of an advanced method to treat obesity, using animal models.


  • Received GAP funding for his project “Evaluation of the Efficacy of Novel Anti-fibrotic Drugs Targeting Type I Collagen,” with the mission statement to screen available drug libraries and validate the ability of selected compounds to prevent formation of Type I collagen in living tissue. Success could lead to major improvements in health for large groups of people now likely to suffer from liver cirrhosis, scleroderma and other collagen-related conditions.
  • Submitted disclosure statements regarding “Discovery of Antifibrotic Drugs Targeting Synthesis of Type I Collagen.”


  • Received GAP funding for his project “Novel Treatment of Traumatic Brain Injury (TBI),” with the mission statement to test the efficacy and safety of an advanced method to minimize damage from mild concussions and other traumatic brain injuries.
  • Submitted disclosure statements regarding “Prophylactic and Post-Acute Use of Progesterone to Better Outcomes Associated with Concussion.”